Is Donepezil an Antipsychotic? Its True Class Explained

Donepezil is not an antipsychotic. It belongs to a completely different drug class called cholinesterase inhibitors, and it was developed and approved specifically to treat Alzheimer’s disease by boosting levels of a brain chemical called acetylcholine. The confusion is understandable, though, because donepezil can reduce some of the same symptoms that antipsychotics target in dementia patients, including hallucinations, delusions, and aggression. That symptom overlap is probably the single biggest reason people wonder whether the two drugs are in the same category.

What Donepezil Actually Does in the Brain

Acetylcholine is a chemical messenger that neurons use to communicate, and it plays a major role in memory, attention, and learning. In Alzheimer’s disease, the neurons that produce acetylcholine degenerate early and aggressively, which is one reason memory loss is typically the first noticeable symptom. Donepezil works by blocking the enzyme that breaks down acetylcholine after it has been released. The result is that whatever acetylcholine the remaining neurons can still produce lingers longer in the gaps between brain cells, giving it more time to do its job.

Animal studies confirm that donepezil administration produces dose-dependent increases in acetylcholine levels in both the cortex and hippocampus, two regions critical for cognition.¹ This mechanism is fundamentally different from what an antipsychotic does. The drug does not sedate, does not target psychosis at its neurochemical root, and was never designed to manage the kinds of symptoms antipsychotics were built to treat. Its primary goal is cognitive: slowing the decline in memory and daily functioning that defines Alzheimer’s progression.²

Why People Confuse Donepezil With Antipsychotics

Alzheimer’s disease and related dementias don’t just erode memory. They often produce what clinicians call behavioral and psychological symptoms of dementia, a cluster that can include hallucinations, paranoid delusions, verbal or physical aggression, wandering, and agitation. These symptoms look a lot like the kinds of problems antipsychotics are traditionally prescribed for in other conditions, so when a doctor prescribes donepezil and a caregiver notices that the patient’s hallucinations or aggression improve, it’s natural to assume the drug must be an antipsychotic.

But the mechanism is different. Donepezil appears to improve these behavioral symptoms as a downstream consequence of restoring cholinergic signaling, not by blocking dopamine the way an antipsychotic would. A Japanese post-marketing survey of donepezil in Alzheimer’s patients with behavioral symptoms found improvement rates of about 60% for hallucinations and delusions, roughly 60% for wandering, and about 66% for aggression.³ A six-month open-label study found that donepezil treatment produced statistically significant improvement in nearly all behavioral symptom domains measured, with the authors concluding that Alzheimer’s-specific drugs may be effective for these symptoms with a favorable safety profile.⁴

One study went further and suggested that cholinesterase inhibitors like donepezil should be tried for behavioral symptoms before antipsychotics are prescribed, particularly in patients whose irritability and agitation are not severe. In that trial, the overall behavioral symptom score dropped significantly during donepezil monotherapy.⁵ None of this makes donepezil an antipsychotic. It makes it a cognitive drug that happens to improve some behavioral symptoms too, likely because cholinergic deficits contribute to those symptoms in the first place.

How Antipsychotics Work Differently

Antipsychotics, whether older “typical” ones like haloperidol or newer “atypical” ones like olanzapine and quetiapine, achieve their effects primarily by blocking dopamine receptors in the brain. That dopamine-blocking action is what reduces psychotic symptoms like hallucinations and delusions in conditions such as schizophrenia. But it also comes with a distinct set of risks that donepezil does not share.

Antipsychotics can cause movement disorders known as extrapyramidal symptoms, which include involuntary muscle contractions, restlessness, tremor, and a shuffling gait that resembles Parkinson’s disease. Newer atypical antipsychotics carry a lower risk of these movement problems at standard doses, but they introduce other concerns: weight gain, elevated blood sugar, unhealthy changes in cholesterol, and cardiovascular disturbances.⁶ These metabolic side effects are a significant long-term worry, particularly in older adults who already face elevated cardiovascular risk.⁷

There is also a serious regulatory concern. In 2005, the FDA issued a black box warning, its most severe safety label, after finding that atypical antipsychotics used in older dementia patients were associated with roughly 1.6 to 1.7 times the risk of death compared with placebo. In 2008, that warning was extended to include conventional antipsychotics as well.⁸ Donepezil carries no such warning. Its side effect profile is dominated by gut-related complaints like nausea and diarrhea, plus occasional dizziness and insomnia, all of which stem from its cholinergic mechanism. The risk landscape of the two drug classes is not even in the same neighborhood.

When Both Drugs Are Prescribed Together

In practice, some dementia patients end up taking donepezil and an antipsychotic simultaneously. The reasoning is straightforward: donepezil for cognition, an antipsychotic for behavioral symptoms that are too severe or dangerous for donepezil alone to manage. But combining the two is not without complications.

Preclinical research in mice found that donepezil, while it did not cause movement problems on its own, significantly worsened the movement side effects caused by haloperidol. The interaction was dose-dependent and synergistic, meaning the combined effect was worse than you would predict by simply adding the two individual effects together.⁹ A separate animal study examining donepezil plus olanzapine similarly warned that extrapyramidal side effects may emerge when the two are given together, cautioning physicians and caregivers to be vigilant.¹⁰

On the other hand, a clinical trial in humans found that combining donepezil with olanzapine for senile dementia yielded significantly better cognitive function scores than olanzapine alone, without a higher rate of adverse reactions.¹¹ The takeaway is that co-prescribing can be beneficial, but it requires careful monitoring. The interaction between donepezil’s cholinergic boost and an antipsychotic’s dopamine blockade creates a neurochemical tension that can tip toward movement problems if the balance is off.

Donepezil in Dementia With Lewy Bodies

One area where the antipsychotic confusion runs especially deep is dementia with Lewy bodies, a condition in which vivid visual hallucinations are a hallmark symptom. Patients and caregivers may assume that any drug addressing those hallucinations must be an antipsychotic. In reality, antipsychotics are particularly risky in Lewy body dementia because patients with this condition tend to have extreme sensitivity to neuroleptic drugs, sometimes developing life-threatening reactions.

Donepezil has been studied as an alternative. A randomized, placebo-controlled trial found that both 5 mg and 10 mg doses of donepezil significantly improved delusions, hallucinations, and cognitive fluctuations in Lewy body dementia patients compared with placebo, where those symptoms actually worsened over the same period.¹² An open-label withdrawal study in patients with Lewy body dementia and Parkinson’s disease dementia similarly found that donepezil improved both cognition and hallucinations without increasing parkinsonian symptoms.¹³ For these patients, donepezil can address some of the symptoms people associate with antipsychotics, while avoiding the very real danger that antipsychotics themselves pose in this population.

Uses Beyond Alzheimer’s Disease

Donepezil’s approved indication is Alzheimer’s disease, but research has pushed it into several other areas. Vascular dementia, which results from impaired blood flow to the brain rather than Alzheimer’s-type pathology, is one of the most studied. A Cochrane review of two large trials involving over 1,200 patients found that donepezil at 5 or 10 mg daily produced statistically significant improvements in cognitive function compared with placebo over 24 weeks.¹⁴ A combined analysis of those same trials confirmed benefits for cognition, global function, and daily activities.¹⁵

More recently, a randomized controlled trial examined donepezil for persistent memory problems after traumatic brain injury. The results were encouraging: donepezil significantly improved verbal learning compared with placebo, with a treatment-responder rate of 42% in the donepezil group versus 18% on placebo. Among those who responded, improvements in delayed recall and processing speed were also significant.¹⁶ None of these uses involve treating psychosis. They all center on cognition, which is squarely in the wheelhouse of a cholinesterase inhibitor.

A Hidden Layer of Pharmacology

Donepezil’s classification as a cholinesterase inhibitor is accurate but incomplete. Research has shown that it also acts as a high-affinity agonist at sigma-1 receptors, a binding site in the brain involved in neuroprotection, memory modulation, and cellular stress responses. A human brain imaging study using positron emission tomography found that a single 5 mg dose of donepezil occupied about 58% of sigma-1 receptors, while a 10 mg dose occupied roughly 76%.¹⁷ Those are substantial occupancy rates, not a trivial side-binding.

Mouse studies suggest this sigma-1 activity contributes to donepezil’s protective effects against amyloid-induced brain damage. When researchers blocked sigma-1 receptors with an antagonist, donepezil’s neuroprotective and memory-preserving effects were significantly reduced, indicating that the drug’s benefits are not entirely explained by its cholinesterase inhibition alone.¹⁸ Further work found that the synergy between sigma-1 receptor activation and donepezil’s cholinergic effects may involve a specific type of nicotinic acetylcholine receptor.¹⁹

This dual mechanism is interesting precisely because it still has nothing to do with antipsychotic pharmacology. Sigma-1 receptor activity is associated with cellular resilience and neuroplasticity, not with dopamine blockade or sedation. If anything, it adds another dimension to donepezil’s identity as a cognitive and neuroprotective agent rather than pulling it closer to the antipsychotic category.

How Donepezil Was Discovered

The drug’s origins reinforce its identity. Donepezil emerged from a deliberate search for a better cholinesterase inhibitor. The earliest drugs in this class, physostigmine and tacrine, showed modest cognitive benefits in Alzheimer’s patients but came with serious drawbacks: physostigmine had poor oral absorption and limited brain penetration, while tacrine caused liver toxicity. Researchers set out to find a compound that would inhibit acetylcholinesterase more selectively and safely. After discovering a promising starting compound somewhat by chance, a team spent four years refining it through systematic chemical modifications before arriving at donepezil.²⁰²¹ At no point in its development was it designed, tested, or evaluated as an antipsychotic. It was always an Alzheimer’s drug built on the cholinergic hypothesis.

What Happens When Donepezil Is Stopped Abruptly

One practical question for patients and caregivers is what to expect if donepezil is discontinued, because the behavioral fallout can sometimes look alarming in ways that further blur the drug class confusion. An open-label trial in patients with Lewy body dementia and Parkinson’s disease dementia found that sudden withdrawal of donepezil typically produced acute cognitive and behavioral decline. While restarting the drug appeared to reverse the deterioration, the authors advised against abrupt discontinuation.¹³

A case report described a patient whose symptoms worsened after donepezil was stopped, progressing all the way to delirium. When donepezil was restarted, the delirium resolved and the patient’s mental state stabilized.²² A caregiver watching someone spiral into confusion and agitation after stopping a medication might reasonably assume that the drug was managing psychosis, reinforcing the misconception that it must have been an antipsychotic. In reality, the withdrawal syndrome reflects the sudden loss of cholinergic support in a brain that has come to depend on it. The biology is entirely consistent with donepezil’s true class.

Donepezil as a Bridge Away From Antipsychotics

Perhaps the most practical implication of understanding donepezil’s real drug class is recognizing it as a potential alternative to antipsychotics, not a member of the same family. Given the FDA’s black box warning on antipsychotic use in elderly dementia patients, there is genuine clinical pressure to find other options for managing hallucinations, aggression, and agitation. Donepezil won’t replace an antipsychotic in every scenario; severe, treatment-resistant psychotic symptoms may still require dopamine-blocking medication. But for mild to moderate behavioral symptoms in Alzheimer’s or Lewy body dementia, donepezil offers a way to address the problem through a different and generally safer biological pathway.

One case report even explored donepezil’s cholinergic mechanism in reverse: a patient experiencing delirium from an overdose of a strongly anticholinergic drug, amitriptyline, recovered rapidly after donepezil was started. The authors proposed that cholinesterase inhibitors might be an effective option for managing delirium caused by anticholinergic poisoning.²³ While a single case report does not establish standard practice, it illustrates how central the cholinergic mechanism is to everything donepezil does. Whether the drug is improving memory, reducing hallucinations, or resolving delirium, the underlying story is always the same: more acetylcholine activity in a brain that doesn’t have enough.